Corante

About this Author
Derek Lowe
Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
MedChem Buzz
Kilomentor
On Pharma
A New Merck, Reviewed
Liberal Arts Chemistry
One in Ten Thousand
Electron Pusher
Periodic Tabloid
All Things Metathesis
C&E News Blog
Propter Doc
Chemiotics II
The Chemical Notebook
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
Chirality
BBSRC/Douglas Kell
ChemBark
Drug Discovery Opinion
Realizations in Biostatistics
Chemjobber
Pharmalot
WSJ Health Blog
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Useful Chemistry
Chiral Jones
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Totally Synthetic
Fragment Literature
The F- Blog
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Carbon-Based Curiosities
Experimental Error
Business|Bytes|Genes|Molecules
Eye on FDA
Sigma-Aldrich ChemBlogs
Chemical Forums
Depth-First
Symyx Blog
P212121
ChemCafe
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
A Scientist's Life
Speculist
Cosmic Variance
The Capsule
Zeroth Order Approximation
Biology News Net


Medical Blogs
Med Tech Sentinel
DB's Medical Rants
Science-Based Medicine
GruntDoc
The Health Care Blog
Respectful Insolence
Black Triangle
Diabetes Mine


Economics and Business
Marginal Revolution
Arnold Kling
The Volokh Conspiracy
Knowledge Problem
The Stalwart


Politics / Current Events
Virginia Postrel
Tinkerty Tonk
Instapundit
Megan McArdle
Mickey Kaus
Colby Cosh
Alien Corn
No Watermelons


Belles Lettres
Two Blowhards
Critical Mass
Arts and Letters Daily
God of the Machine
Armavirumque
About Last Night
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« A Rough Business | Main | Looking Back, Looking Forward »

December 16, 2002

Attitude

Email This Entry

Posted by Derek

Now that I've had a chance to look over the Wall Street Journal's article on Bristol-Meyers Squibb, it occurs to me that I've seen this behavior many times. I don't mean the financial voodoo (although I've seen that at second hand, just like anyone else who pays attention to the markets.) What I mean is the attitude that leads to it.

BMS got into this trouble because they promised 12% sales growth, right into the headwind of patent expirations on things like Glucophage and Taxol. The failure of Vanlev took them by surprise, just like it took everyone else, but it's not like they didn't know that those patent expirations were coming. Promising that kind of growth was arrogant and completely unrealistic, and that's the attitude I'm talking about.

Now, there are plenty of arrogant scientists in this world. But we're all supposed to look at the data and be willing to listen to what it says, even if we don't like it. You really can't make it in science unless you're willing to do that, and it keeps you from getting as full of yourself as you might otherwise get. Some of your ideas are just not going to work, because the universe isn't set up to let them work.

But there's a worldview common to athletic coaches, motivational speakers, and CEOs, and it says that failure is not an option. If you do fail, then you obviously didn't have the killer instinct, the grit, the tenacity, the fire in the belly. You just didn't want it enough. Sound familiar? This outlook can work when you're dealing with things that can be browbeaten (like other people.) It might work on scientists, but a lot of good that'll do, because it won't work on their science.

Now, it's true that your researchers need to be motivated, and need to keep pushing to accomplish things. That's why, in spite of all its inefficient craziness, I think that having dozens of drug companies fighting it out is a good thing, because it keeps us all on our toes. And you need tenacity to do good research, because most good ideas only get around to working after about the eighteenth try. These things are necessary - my point is that they're not sufficient.

And that's where this hard-charging attitude breaks down. It's all very well to yell at the sales force - it might even stir them up, until they all go find other jobs, since they're people dealing with other people. But are you really going to do that with the researchers and patent lawyers, with the clinical teams and the bioinformatics people? I've sat through meetings where people tried, and if eye-rolling made a noise, you wouldn't have been able to hear yourself think.

No amount of table-pounding will make a clinical trial turn out the way you want it to. No talk is tough enough to convince a protein assay to tell you that your compounds are active. You can rant at the rats all you want, but they'll continue to do whatever pleases them, and it's up to you to figure out what it all means. The physical universe cannot be sweet-talked, conned, or intimidated. It is what it is, and it does what it does.

Comments (0) + TrackBacks (0) | Category: Who Discovers and Why


COMMENTS

EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Academia and Industry, Suing Each Other
Let's Start Off the Meeting With An Ad, OK?
The Academic-Industrial Collaboration in Drug Discovery Panel: Today
Glass Structure, Atom by Atom
How the Andrulis Paper Got Published
AstraZeneca in Waltham
Fluorine NMR: Why Not?
AstraZeneca Layoffs and Closings